Maryland § 13-518

§ 13-518.

    (a)    (1)    In this section the following words have the meanings indicated.

        (2)    “Automated external defibrillator (AED)” has the meaning stated in § 13–517 of this subtitle.

        (3)    “Naloxone” means the medication approved by the federal Food and Drug Administration for community use for the reversal of a known or suspected opioid overdose.

        (4)    “Public building” means:

            (i)    A public mass transportation accommodation, such as a terminal or station, that is supported by public funds;

            (ii)    An improvement of a public area used for gathering or amusement, including a public park or recreation center; or

            (iii)    A facility that is supported by public funds and primarily used to provide secondary or higher education.

    (b)    (1)    The EMS Board, in collaboration with the Maryland Department of Health, shall develop and implement an initiative under the Public Access Automated External Defibrillator Program to require that naloxone be co–located with each automated external defibrillator placed in a public building.

        (2)    The initiative developed under paragraph (1) of this subsection shall ensure that up to two doses of naloxone are maintained in a location that:

            (i)    Is visible and in close physical proximity to the automated external defibrillator; and

            (ii)    Has a label that clearly indicates to the public the availability of naloxone.

        (3)    The initiative developed under paragraph (1) of this subsection shall be funded using funds from the Opioid Restitution Fund appropriated through the State budget.

    (c)    (1)    The owner or operator of a public building is not civilly liable for any act or omission in the provision and maintenance of naloxone under the initiative developed under subsection (b)(1) of this section if the owner or operator has satisfied any requirements established for providing and maintaining naloxone under the initiative.

        (2)    An individual who administers naloxone made available under the initiative developed under paragraph (1) of this subsection in response to a known or suspected drug overdose shall have immunity from civil liability as provided in § 5–603 of the Courts Article.

    (d)    The EMS Board and the Maryland Department of Health jointly shall adopt regulations that:

        (1)    Establish guidelines for periodic inspections and maintenance of the naloxone placed in public buildings;

        (2)    Assist the administrators of each public building in carrying out the provisions of this section; and

        (3)    Establish initial prioritization of the public buildings eligible to receive funding under this section with a goal of co–location of naloxone with each automated external defibrillator located in a public building by October 1, 2027.